Evidence map›Paper›PMID 34580764›Full record

ArticleCancer immunology, immunotherapy : CII2022

Analysis of T cell receptor clonotypes in tumor microenvironment identifies shared cancer-type-specific signatures.

Yvonne H F Teng, Hong Sheng Quah, Lisda Suteja, João M L Dias, Annalisa Mupo, Rachael J M Bashford-Rogers, George S Vassiliou, Melvin L K Chua, Daniel S W Tan, Darren W T Lim and 1 more

Erratum issuedOpen access · bronzeAbstract read
In one paragraph

Article in Cancer immunology, immunotherapy : CII, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 12 papers.

0numbers the graph read from it
0cells of the map it votes in
12citing papers in PubMed
0.5field-weighted citation impact, top 39% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

12 citing papers in PubMed, 13 citations in OpenAlex.

  1. Circulating CD28Journal of translational medicine · 2026
    Article
  2. Article
  3. Article
  4. Review
  5. Article
  6. Article
  7. Article
  8. Article
  9. Article
  10. Article
  11. Article
  12. Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

11 authors at 8 institutions in 2 countries.

Yvonne H F TengCancer Therapeutics Research Laboratory, National Cancer Centre Singapore, 11 Hospital Crescent, Singapore, 169610, Singapore.ORCID http://orcid.org/0000-0002-4242-486X
Hong Sheng QuahCancer Therapeutics Research Laboratory, National Cancer Centre Singapore, 11 Hospital Crescent, Singapore, 169610, Singapore.
Lisda SutejaCancer Therapeutics Research Laboratory, National Cancer Centre Singapore, 11 Hospital Crescent, Singapore, 169610, Singapore.
João M L DiasHutchison/MRC Research Centre, MRC Cancer Unit, University of Cambridge, Cambridge Biomedical Campus, Cambridge, CB2 0XZ, UK.
Annalisa MupoBabraham Research Institute, Cambridge, CB22 3AT, UK.
Rachael J M Bashford-RogersWellcome Trust Centre for Human Genetics, University of Oxford, Roosevelt Dr, Headington, Oxford, OX3 7BN, UK.
George S VassiliouWellcome-MRC Cambridge Stem Cell Institute, Jeffrey Cheah Biomedical Centre, University of Cambridge, Cambridge Biomedical Campus, Puddicombe Way, Cambridge, CB2 0AW, UK.
Melvin L K ChuaDuke-NUS Medical School, Singapore, Singapore.
Daniel S W TanCancer Therapeutics Research Laboratory, National Cancer Centre Singapore, 11 Hospital Crescent, Singapore, 169610, Singapore.
Darren W T LimDivision of Medical Oncology, National Cancer Centre Singapore, Singapore, Singapore.
N Gopalakrishna IyerCancer Therapeutics Research Laboratory, National Cancer Centre Singapore, 11 Hospital Crescent, Singapore, 169610, Singapore. gopaliyer@singhealth.com.sg.ORCID http://orcid.org/0000-0002-8812-6219
Duke-NUS Medical School · SGAgency for Science, Technology and Research · SGBabraham Institute · GBCentre for Human Genetics · GBNational Cancer Centre Singapore · SGSingHealth · SGUniversity of Cambridge · GBWellcome/MRC Cambridge Stem Cell Institute · GB

Funding

Cancer Research UK 23015Medical Research Council MC_PC_17230
6 · The paper itself

Abstract

Despite the conventional view that a truly random V(D)J recombination process should generate a highly diverse immune repertoire, emerging reports suggest that there is a certain bias toward the generation of shared/public immune receptor chains. These studies were performed in viral diseases where public T cell receptors (TCR) appear to confer better protective responses. Selective pressures generating common TCR clonotypes are currently not well understood, but it is believed that they confer a growth advantage. As very little is known about public TCR clonotypes in cancer, here we set out to determine the extent of shared TCR clonotypes in the intra-tumor microenvironments of virus- and non-virus-driven head and neck cancers using TCR sequencing. We report that tumor-infiltrating T cell clonotypes were indeed shared across individuals with the same cancer type, where the majority of shared sequences were specific to the cancer type (i.e., viral versus non-viral). These shared clonotypes were not particularly enriched in EBV-associated nasopharynx cancer but, in both cancers, exhibited distinct characteristics, namely shorter CDR3 lengths, restricted V- and J-gene usages, and also demonstrated convergent V(D)J recombination. Many of these shared TCRs were expressed in patients with a shared HLA background. Pattern recognition of CDR3 amino acid sequences revealed strong convergence to specific pattern motifs, and these motifs were uniquely found to each cancer type. This suggests that they may be enriched for specificity to common antigens found in the tumor microenvironment of different cancers. The identification of shared TCRs in infiltrating tumor T cells not only adds to our understanding of the tumor-adaptive immune recognition but could also serve as disease-specific biomarkers and guide the development of future immunotherapies.

Indexed as

NeoplasmsTumor MicroenvironmentHumansReceptors, Antigen, T-CellT-LymphocytesReceptors, Antigen, T-CellImmune repertoire sequencingPublic TCRT cell receptorTCR sharingTumor-infiltrating T cells

Identifiers

PMID34580764
PMCPMC8476067
OpenAlexW3204749855

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.